Product news

Share this content:
Amgen said the European Commission has granted a conditional marketing authorization for Vectibix (panitumumab) as monotherapy for the treatment of patients with epidermal growth factor receptor expressing metastatic colorectal cancer with non-mutated (wild-type) KRAS genes after failure of standard chemotherapy regimens.
Share this content:
Scroll down to see the next article